Cordis launches new PTA Balloon Catheter to treat PAD

NewsGuard 100/100 Score

Cordis Corporation is pleased to announce the launch of SLEEK® OTW Catheter, a new .014" Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter designed to help physicians save limbs and enhance patients' lives. This new PTA Balloon was first launched at LINC (Leipzig Interventional Course, Leipzig, Germany) and ISET (International Symposium on Endovascular Therapy, Miami, Florida) earlier this year.

Lower limb amputation is a last resort for many patients with end-stage peripheral arterial disease (PAD), also known as critical limb ischemia. It is estimated that as many as 160,000 lower limbs are amputated every year in the U.S. and 60-70 percent of these amputations are performed as the first-line therapy. These lower-limb amputations come with a mortality rate of as much as 70% at five years. Cordis Corporation's SLEEK® OTW Catheter is the latest technology designed to restore blood flow to the lower limbs, which helps physicians save limbs and enhance patients' lives.

The SLEEK® OTW Catheter has a unique balance of excellent pushability with a small crossing profile that helps physicians reach small arteries below-the-knee and into the foot to restore blood flow to the lower limb. A broad portfolio of sizes is also offered with PTA balloon diameters of 1.25mm to 5.0mm and lengths up to 220mm that allow physicians to treat diffuse disease with fewer inflations. With the SLEEK® OTW Catheter, physicians can treat complex below-the-knee disease with confidence.

"The SLEEK® OTW Catheter offers our most advanced technology designed to treat challenging below the knee disease," said Campbell Rogers, MD, Chief Scientific Officer, Global Head R&D. "This addition to our Lower Extremity product portfolio underscores our commitment to providing solutions that help save limbs and improve the quality of life for patients with advanced peripheral vascular disease."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Drug-coated balloon shows superiority in coronary in-stent restenosis treatment